ESC Premium Access

The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation

Presentation

About the speaker

Doctor Peter Noseworthy

Mayo Clinic, Rochester (United States of America)
1 presentation
0 follower

6 more presentations in this session

Adherence to anticoagulant drugs in patients with atrial fibrillation and stroke in real clinical practice

Speaker: Professor D. Duplyakov (Samara, RU)

Thumbnail

Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Thumbnail

Periprocedural anticoagulation is associated with the risk of thromboembolism after elective cardioversion of atrial fibrillation.

Speaker: Doctor T. Hellman (Turku, FI)

Thumbnail

Reduced fibrin clot permeability is associated with an increased risk of both ischemic stroke and major bleeding in atrial fibrillation patients treated with vitamin k antagonists

Speaker: Professor A. Undas (Krakow, PL)

Thumbnail

Use of novel oral anticoagulants in patients with atrial fibrillation and moderate to severe renal dysfunction: findings from a prospective national registry

Speaker: Professor I. Goldenberg (Rochester, US)

Thumbnail

Access the full session

Progress in stroke prevention in atrial fibrillation

Speakers: Doctor P. Noseworthy, Professor D. Duplyakov, Doctor A. Nissen Bonde, Doctor T. Hellman, Professor A. Undas...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk